MedTrace Logo

A Study for Patients With Relapsing Remitting Multiple Sclerosis

NCT00869986 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 218

Last updated 2010-09-09

No results posted yet for this study

Summary

The purpose of this study is to test if dirucotide is safe and effective in treating patients with relapsing remitting multiple sclerosis.

Conditions

  • Relapsing Remitting Multiple Sclerosis

Interventions

DRUG

dirucotide

500mg, intravenous, every 6 months for 15 months

DRUG

placebo

intravenous, once every six months for 15 months

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9am - 5pm Eastern Time (UTC/GMT)-5 hours,EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-11-30
Primary Completion
2009-09-30
Completion
2009-09-30

Countries

  • Bulgaria
  • Poland
  • Russia
  • Serbia
  • Slovakia
  • Ukraine

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00869986 on ClinicalTrials.gov